Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT IV trial investigators. Weller M, et al. Among authors: mechtler l. Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23. Lancet Oncol. 2017. PMID: 28844499 Free article. Clinical Trial.
Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design.
Ho TW, Pearlman E, Lewis D, Hämäläinen M, Connor K, Michelson D, Zhang Y, Assaid C, Mozley LH, Strickler N, Bachman R, Mahoney E, Lines C, Hewitt DJ; Rizatriptan Protocol 082 Pediatric Migraine Study Group. Ho TW, et al. Cephalalgia. 2012 Jul;32(10):750-65. doi: 10.1177/0333102412451358. Epub 2012 Jun 18. Cephalalgia. 2012. PMID: 22711898 Clinical Trial.
Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review.
Blumenfeld AM, Mechtler L, Cook L, Rhyne C, Jenkins B, Hughes O, Dabruzzo B, Manack Adams A, Diamond M. Blumenfeld AM, et al. Among authors: mechtler l. Pain Ther. 2024 Dec;13(6):1571-1587. doi: 10.1007/s40122-024-00649-8. Epub 2024 Sep 17. Pain Ther. 2024. PMID: 39287781 Free PMC article.
Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study.
Ailani J, Lipton RB, Blumenfeld AM, Mechtler L, Klein BC, He MY, Smith JH, Trugman JM, de Abreu Ferreira R, Brand-Schieber E. Ailani J, et al. Among authors: mechtler l. Headache. 2024 Nov 21. doi: 10.1111/head.14871. Online ahead of print. Headache. 2024. PMID: 39569702
Towards cascading genetic risk in Alzheimer's disease.
Altmann A, Aksman LM, Oxtoby NP, Young AL; ADNI; Alexander DC, Barkhof F, Shoai M, Hardy J, Schott JM. Altmann A, et al. Brain. 2024 Aug 1;147(8):2680-2690. doi: 10.1093/brain/awae176. Brain. 2024. PMID: 38820112 Free PMC article.
Fluid suppression in amide proton transfer-weighted (APTw) CEST imaging: New theoretical insights and clinical benefits.
Schüre JR, Casagranda S, Sedykh M, Liebig P, Papageorgakis C, Mancini L, Bisdas S, Nichelli L, Pinter N, Mechtler L, Jafari R, Boddaert N, Dangouloff-Ros V, Poujol J, Schmidt M, Doerfler A, Zaiss M. Schüre JR, et al. Among authors: mechtler l. Magn Reson Med. 2024 Apr;91(4):1354-1367. doi: 10.1002/mrm.29915. Epub 2023 Dec 10. Magn Reson Med. 2024. PMID: 38073061
Tominersen in Adults with Manifest Huntington's Disease.
McColgan P, Thobhani A, Boak L, Schobel SA, Nicotra A, Palermo G, Trundell D, Zhou J, Schlegel V, Sanwald Ducray P, Hawellek DJ, Dorn J, Simillion C, Lindemann M, Wheelock V, Durr A, Anderson KE, Long JD, Wild EJ, Landwehrmeyer GB, Leavitt BR, Tabrizi SJ, Doody R; GENERATION HD1 Investigators. McColgan P, et al. N Engl J Med. 2023 Dec 7;389(23):2203-2205. doi: 10.1056/NEJMc2300400. N Engl J Med. 2023. PMID: 38055260 No abstract available.
Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
Lipton RB, Halker Singh RB, Mechtler L, McVige J, Ma J, Yu SY, Stokes J, Dabruzzo B, Gandhi P, Ashina M. Lipton RB, et al. Among authors: mechtler l. Cephalalgia. 2023 Aug;51(8):3331024231190296. doi: 10.1177/03331024231190296. Cephalalgia. 2023. PMID: 37638400 Free article. Clinical Trial.
87 results